BiotechTube
TheracosBio

TheracosBio

Marlborough, United States· Est.
theracosbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

TheracosBio is a commercial-stage biotech company commercializing Brenzavvy, an SGLT2 inhibitor for type 2 diabetes, with a distinct business model based on affordable pricing to drive rapid market penetration. The company leverages an experienced leadership team with deep expertise in regulatory affairs, clinical development, and supply chain management. Its strategy involves forging partnerships with pharmacies and distributors to ensure low-cost access, positioning it uniquely in the competitive diabetes market. TheracosBio aims to address healthcare disparities by making newer therapeutics accessible to a broader patient population immediately upon approval.

Metabolic DiseaseType 2 Diabetes

Technology Platform

Commercial strategy platform focused on developing/launching affordable small molecule drugs for prevalent diseases, emphasizing low pricing from approval to enable broad access.

Funding History

2
Total raised:$60M
Series B$40M
Series A$20M

Opportunities

The large and growing type 2 diabetes patient population, combined with widespread dissatisfaction with high drug prices and increasing policy focus on affordability, creates a major opportunity for Brenzavvy's low-cost model.
Expansion into international markets with high diabetes burden and cost sensitivity, like Sub-Saharan Africa, represents significant growth potential.
Success with the first product could validate the company's strategy, enabling expansion into other common chronic disease areas.

Risk Factors

The company faces extreme concentration risk with only one commercial product.
It competes against entrenched, well-funded rivals in the SGLT2 inhibitor market who have broader formulary access and more extensive outcome data.
The low-margin, volume-dependent business model is operationally challenging and leaves little room for error in execution or supply chain disruptions.

Competitive Landscape

Brenzavvy competes in the established SGLT2 inhibitor class, directly against major branded products like Jardiance (empagliflozin/Boehringer Ingelheim/Eli Lilly), Farxiga (dapagliflozin/AstraZeneca), and Invokana (canagliflozin/Janssen). These competitors have strong brand recognition, extensive clinical data including cardiovascular outcome trials, and deep relationships with payers. TheracosBio's primary competitive differentiation is its disruptive low price point, targeting cost-conscious patients, pharmacies, and payers.

More companies in Small Molecule Drugs →More companies in United States →